Mr. Charles MaLette reports

SURENANO SCIENCE INITIATES FDA STAGE GLP TOXICOLOGY AND PHARMACOLOGY STUDIES FOR GLP GEP-44 AND ENTERS DISCUSSIONS TO ACQUIRE IBOGAINE FORMULATION IP PORTFOLIO

Surenano Science Ltd. is planning a comprehensive U.S. Food and Drug Administration (FDA) pathway IND-enabling (investigational new drug) good laboratory practice (GLP) toxicology and pharmacology study program for its lead candidate, GEP-44. The program is expected to be conducted in collaboration with a premier global clinical research organization (CRO), LabCorp, known for its expertise in preclinical development, subject to entering into definitive collaboration agreements and the financing of related amounts.

This pivotal, GLP-compliant package is specifically designed to assess safety, toxicology and pharmacology across multiple species, including rodents and non-rodent primates, to evaluate the safety and feasibility of the approach for human clinical application. The studies will provide comprehensive data to determine the maximum tolerated dose (MTD), identify potential biomarkers for monitoring toxicity, assess the reversibility of toxic effects, and establish the safety margin needed for first-in-human studies.

"Initiating these U.S. Food and Drug Administration (FDA) IND-enabling studies is a major milestone for Surenano Science and GlucaPharm, moving us firmly towards the final, rigorous evaluation in various clinical phases before entering the clinic," said Dr. Nihar Pandey, PhD, chief scientific officer at Surenano. "Partnering with a globally renowned CRO like LabCorp will ensure our studies meet the highest regulatory standards. This package is vital to derisk our lead candidate and is designed to support our strategy of launching a phase I clinical trial in Australia."

Following the successful completion of these studies, Surenano intends to submit a clinical trial notification (CTN) in Australia to begin FDA phase I testing in patients. Australia is chosen for its efficient regulatory framework, high-quality research infrastructure and accelerated path to first-in-human studies.

With the progression of its lead asset, GEP-44, a novel, patented peptide developed by researchers at Syracuse University, similar in function to Ozempic, Wegovy, Mounjaro and Retatrutide, targeting comparable or superior efficacy, improved patient tolerability and delivery potential, Surenano is positioning itself in a highly competitive and fast-growing therapeutic space where even incremental advances can have large commercial impact.

Addition of ibogaine intellectual property opportunity to company portfolio

U.S. President Donald Trump recently signed an executive order designed to fast-track both research on and access to these psychedelic drugs with a focus on ibogaine, including a $50-million investment in state governments to study how psychedelics might help people struggling with mental health illnesses.

The FDA also issued IND clearance for Ibogaine to allow for human testing. Given this, the company now has a clearance for ibogaine, which will allow for human clinical trials for the first time in the United States, paving the way for more research and, ultimately, a development of commercial FDA-approved treatment options using ibogaine.

The company believes ibogaine and next-generation ibogaine analogues have demonstrated potential in addressing addiction and mental health disorders, including opioid dependence and PTSD (posttraumatic stress disorder) symptoms through mechanisms believed to involve modulation of multiple neurotransmitter systems and neuroplasticity pathways. Mr. Trump and superinfluencer Joe Rogan have commented on the merits of ibogaine-based treatments.

Surenano has initiated discussions with academic institutions and independent research groups to evaluate opportunities to license or acquire intellectual property related to the synthesis, formulation and delivery of ibogaine and structurally related compounds.

Discussions remain at an early stage, and there can be no assurance that any transaction or licensing agreement will be completed. The company will provide further updates as material developments occur.

Investor outreach and awareness campaign agreement

The company is also pleased to announce various strategic marketing and investor relations engagements with arm's-length independent contractors and agencies, with the aim of developing the company's communication strategy and strengthening exposure to a wider audience.

Emerging Growth LLC

A media agency agreement dated April 22, 2026, has been executed by the company with Emerging Growth (doing business as TDM Financial), a U.S.-based firm specializing in investor-focused marketing and communications. Under the terms of the TDM Financial service agreement, TDM Financial will execute a comprehensive investor outreach and awareness campaign over a six-month period, which commenced on April 22, 2026. The campaign is designed to reach a broad audience of highly targeted investors across the United States and Canada through a combination of digital media channels and social platforms. Key elements of the campaign include distribution of sponsored, native-style content across leading financial websites and investor-focused social media platforms, including X (formerly Twitter), Reddit, TikTok and LinkedIn, and the development and production of multimedia content, including videos, infographics and editorial articles, tailored to communicate the company's corporate story and growth strategy. In accordance with the terms and conditions of the TDM Financial service agreement and as consideration for the services provided by TDM Financial, the company has agreed to pay TDM Financial a total cash consideration of $26,667 (U.S.), payable in instalments over the duration of the agreement. TDM Financial and its principals are arm's length from the company and do not have any interest, direct or indirect, in the company or its securities, nor do they have any right or intent to acquire such an interest. TDM Financial's business is located at 600 East 8th St., Whitefish, Mont., United States, 59937, and the contact information is as follows.

Telephone:   1-206-369-7050

E-mail:  flane@cfnmedia.com

Investor Brand Network

A media agency agreement dated April 23, 2026, has been executed by the company with Investor Brand Network (doing business as IBN), a multifaceted financial media and communications organization, to support the company's investor awareness strategy. IBN will leverage its extensive syndication network, which includes over 5,000 media outlets, newsletters, social channels and wire services, to expand the company's reach to a broader U.S. investor audience. With more than 20 years of experience and a record of serving over 600 public and private clients, IBN delivers comprehensive communications solutions through its network of financial brands and syndication partners. Under the terms of the agreement, IBN will provide corporate communication and awareness solutions to the company over a six-month initial period commencing on May 4, 2026. IBN will assist Surenano in refining and strengthening its market awareness profile with the goal of maximizing shareholder value. In accordance with the terms and conditions of the IBN service agreement and as consideration for the services provided by IBN, the company has agreed to pay IBN a quarterly cash consideration of $29,000 (U.S.), over the duration of the agreement, then quarter to quarter after the first six-month term, until cancellation. IBN and its principals are arm's length from the company and do not have any interest, direct or indirect, in the company or its securities, nor do they have any right or intent to acquire such an interest. IBN's business is located at 1108 Lavaca St., Suite 110, Austin, Tex., United States, 78701, and the contact information is as follows.

Telephone:  1-512-354-7000

E-mail:  Editor@InvestorBrandNetwork.com

The Market Link (iHub)

A media agency agreement dated April 23, 2026, has been executed by the company with iHub Inc. (doing business as The Market Link (TML)), a global department and brand, operated and owned entirely by TML, pursuant to which TML has agreed to provide a marketing campaign, as part of which it will execute an enhanced news release distribution for the company, including news blast and forum boost advertising. The TML service agreement remains in effect until the retainer and inventory are depleted, with services commencing on April 24, 2026, the campaign period, and will not automatically renew. In accordance with the terms and conditions of the TML service agreement and as consideration for the services provided by TML, the company has agreed to provide TML with a one-time cash fee of $10,000 (U.S.) plus applicable taxes. TML and its principals are arm's length from the company and do not have any interest, direct or indirect, in the company or its securities, nor do they have any right or intent to acquire such an interest. TML's business is located at P.O. Box 780, Harrisonville, Mo., 64701, United States, and the contact information is as follows.

Telephone:  1-778-588-7012

E-mail:  support@advfn.com

Milky Way Marketing Inc. and Blue Sun Productions Inc. (BTV)

A service agreement dated Feb. 23, 2026, has been executed by the company with Milky Way Marketing and Blue Sun Productions (BTV), a marketing and content agency. Pursuant to the terms and conditions of the BTV service agreement, BTV has agreed to provide the company with a marketing and broadcast package that includes a 30-second produced graphical-style TV spot for broadcast, TV ad spots and 40 BNN Bloomberg broadcasts, along with a stock ticker ad and newsletter e-blast. BTV will provide its services until the ads have been completed running or for a period of approximately six weeks, with ads to begin running on or around May 1, 2026. In accordance with the terms and conditions of the BTV service agreement and as consideration for the services provided by BTV, the company has agreed to pay BTV a cash fee of $22,300 plus GST (goods and services tax) to be added where applicable. BTV and its principals are arm's length from the company and do not have any interest, direct or indirect, in the company or its securities, nor do they have any right or intent to acquire such an interest. BTV's business is located at Suite 17, 19257B Enterprise Way, Surrey, B.C., Canada, and the contact information is as follows.

Telephone:  1-604-664-7401

E-mail:  jessica@b-tv.com

Stock option grant

Surenano also announces that it has granted 1.5 million stock options to various directors, officers and consultants of the company. The options will vest immediately and may be exercised at an exercise price of 30 cents per common share, for a period of three years from the date of issuance or earlier in accordance with the company's incentive stock option plan.

About Surenano Science Ltd.

Surenano Science is a Canadian life sciences company focused on acquiring, developing and advancing innovative pharmaceutical and biotechnology assets with the potential to address large and growing global health markets. Surenano Science has acquired GlucaPharm Inc., a next-generation GLP-1 pharmaceutical company developing GEP44, a patented peptide targeting obesity and metabolic disorders with improved tolerability and potential non-injectable delivery (refer to press release dated Feb. 23, 2026). The initial business of Surenano Science is the sale and distribution of the Surenano surfactant, which is a ready-to-mix food-grade compound that provides the base for high-performance nanoemulsions to create incredibly homogeneous and stable products while maximizing bioavailability, clarity and taste. The company has an exclusive licence to distribute the Surenano surfactant within Canada, Oklahoma (United States) and Colorado (United States). Surenano Science is now developing into a pharmaceutical-focused company through the advancement of a patented therapeutic candidate designed to address obesity and metabolic disease.

We seek Safe Harbor.